01/28/02



			•									
P	erial No	· •	TRANSMITTAL LETTER Filing Date Examiner					Case No. 10466/64 Group Art Unit				
	09/904,	877 July 12, 2001 To be a					assigned Group Art Unit					
	Inventor(s) Ashkenazi et al.											
	Title of I	itle of Invention										
	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME											
	TO THE COMMISSIONER FOR PATENTS											
		Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in comput readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/										
	Amino A	Amino Acid Sequence Disclosures and return postcard. Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted. A verified statement to establish small entity status under 37 CFR § § 1.9 and 1.27 is enclosed. Petition for amonth extension of time. No additional fee is required.										
										reviously		
	\boxtimes											
		The fee has bee	en calculated	d as shown below:								
							Small	Entity		Other Small I		
		Claims		Highest No.]	- Cinaii	Littley		0		
		Remaining		Previously	Present			Add'I	or		Add'l	
		After Amendment		Paid For	Extra		Rate	Fee		Rate	Fee	
ļ	Total		Minus				x \$9=			x \$18=		
	Indep.		Minus				x 42=			x \$84=		
	First Pres	sentation of Mult	iple Dep. Cl	aim			+ \$140 =		_	+ \$280=	,	
							Total add'I fee	\$		Total add'I fee	\$	
		Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A										
duplicate copy of this sheet is enclosed.												
		A check in the amount of \$ to cover the filing fee is enclosed. The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credi any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.										
	M											
	I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely								a timaly			
	الحكا	filed. Please ch	narge any as	sociated fees which	•		-					
		duplicate copy of this sheet is enclosed.										
		Respectfully submitted,										
	W/W w											
	Gregory M. Zinkl, Ph.D. Registration No. 48,492											
	Agent for Applicant BRINKS HOFER GILSON & LIONE											
	P.O. BOX 10395 CHICAGO, ILLINOIS 60610											
(312) 321-4200												
	I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 392680662US, with sufficient postage, in an envelope and ressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on											
	WMan /											
	Date: _g \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \											
	rev. Dec00	,										

JAN 2 5 2002 B

	TRANSMITTAL LET	TER	Case No. 10466/64
Derial No. 09/904,877	Filing Date July 12, 2001	Examiner To be assigned	Group Art Unit
Inventor(s) Ashkenazi et al.			
Title of Invention SECRETED AND TRANS	MEMBRANE POLYPEPTIDES AN	ND NUCLEIC ACIDS ENCODING	THE SAME

TO THE COMMISSIONER FOR PATENTS												
	Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in compute readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/o Amino Acid Sequence Disclosures and return postcard. Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.								computer ce and/or			
									previously			
A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed. Petition for amonth extension of time. No additional fee is required.												
	The fee has be	en calculate	d as shown below	v :						-		
										Other Than		
	Claims		Highart No.		7 [Small	Entity	7	Small Entity			
	Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'l Fee	or	Rate	Add'l Fee		
Total		Minus				x \$9=			x \$18=			
Indep.		Minus				x 42=			x \$84=	,		
First Pre	sentation of Multiple Dep. Claim] [+ \$140 =			+ \$280=			
						Total add'I fee	\$		Total add'l fee	\$		
	Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed.											
A check in the amount of \$ to cover the filing fee is enclosed.												
The Commissioner is hereby authorized to charge payment of any addition 1.16 and any patent application processing fees under 37 CFR § 1.17 associany overpayment to Deposit Account No. 23-1925. A duplicate copy of this							ated with th	is cor	nmunication (
ı				Respectfully	subn	nitted,						
Gregory M. Zinkl, Ph.D. Registration No. 48,492												
Agent for Applicant BRINKS HOFER GILSON & LIONE												
P.O. BOX 10395 CHICAGO, ILLINOIS 60610												
(312) 321	-4200			. /						•		
I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 392680662US, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on Add Told Service as												
Date: N/126/bV Signature: WWW												

rev. Dec.-00



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 www.uspto.gov

ATTORNEY DOCKET NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT APPLICATION NUMBER

09/904.877

07/12/2001

Avi Ashknazi


P1618P2C27

CONFIRMATION NO. 4450

FORMALITIES LETTER

OC000000007149313

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599



Date Mailed: 12/03/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY